Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy.
Elisabetta GodanoFabio BarraAlessandra AllodiAntonella FerraioloAlice LaroniGiovanni NoviGiovanni Luigi MancardiClaudio GustavinoCesare ArioniPublished in: Italian journal of pediatrics (2021)
This case report confirmed that natalizumab can cause disorders of hematopoiesis, including anemia, thrombocytopenia, or pancytopenia, in newborns of patients treated during pregnancy. A multidisciplinary team, including experienced pediatricians and pediatric hematologists, has a critical role in managing newborns delivered by women, being treated with natalizumab for treating relapsing-remitting multiple sclerosis during pregnancy.
Keyphrases
- multiple sclerosis
- case report
- pregnant women
- chronic kidney disease
- pregnancy outcomes
- iron deficiency
- gestational age
- white matter
- low birth weight
- preterm birth
- cord blood
- polycystic ovary syndrome
- quality improvement
- preterm infants
- metabolic syndrome
- stem cells
- rheumatoid arthritis
- bone marrow
- recombinant human
- newly diagnosed
- systemic lupus erythematosus
- cervical cancer screening
- skeletal muscle
- smoking cessation
- insulin resistance
- cell therapy